| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $68,776,661 | 12 | 100 |
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 0 | $0 | 1 | $2.64M | $-2.64M |
| Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | 0 | $0 | 1 | $3.75M | $-3.75M |
| Buckbee Kevin K | SVP, CONTROLLER | 0 | $0 | 1 | $3.85M | $-3.85M |
| Siatis Perry C | EVP, GC AND SECRETARY | 0 | $0 | 3 | $6.97M | $-6.97M |
| SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | 0 | $0 | 1 | $8.41M | $-8.41M |
| RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | 0 | $0 | 2 | $10.54M | $-10.54M |
| Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | 0 | $0 | 1 | $12.36M | $-12.36M |
| GONZALEZ RICHARD A | director | 0 | $0 | 2 | $20.26M | $-20.26M |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Over the last 12 months, insiders at AbbVie Inc. have bought $0 and sold $68.78M worth of AbbVie Inc. stock.
On average, over the past 5 years, insiders at AbbVie Inc. have bought $0 and sold $85.26M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 750 shares for transaction amount of $51,750 was made by Durkin Brian L (VP, Controller) on 2020‑03‑30.
| 2025-08-12 | Sale | SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | 42,370 0.0024% | $198.42 | $8.41M | +13.19% | |
| 2025-08-05 | Sale | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 13,295.17 0.0008% | $198.51 | $2.64M | +13.18% | |
| 2025-03-31 | Sale | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | 58,832 0.0033% | $210.08 | $12.36M | +3.04% | |
| 2025-03-14 | Sale | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | 17,644 0.001% | $212.34 | $3.75M | +1.15% | |
| 2025-03-03 | Sale | GONZALEZ RICHARD A | director | 6,168 0.0003% | $210.53 | $1.3M | +1.06% | |
| 2025-03-03 | Sale | RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | 21,250 0.0012% | $210.45 | $4.47M | +1.06% | |
| 2025-03-03 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 18,008 0.001% | $210.00 | $3.78M | +1.06% | |
| 2025-02-28 | Sale | GONZALEZ RICHARD A | director | 92,460 0.0052% | $205.11 | $18.96M | +2.18% | |
| 2025-02-28 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 9,892 0.0006% | $206.30 | $2.04M | +2.18% | |
| 2025-02-26 | Sale | RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | 29,917 0.0017% | $202.90 | $6.07M | +5.20% | |
| 2025-02-26 | Sale | Buckbee Kevin K | SVP, CONTROLLER | 18,944 0.0011% | $203.41 | $3.85M | +5.20% | |
| 2025-02-20 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 5,778 0.0003% | $197.90 | $1.14M | +5.99% | |
| 2024-12-16 | Sale | Buckbee Kevin K | SVP, CONTROLLER | 1,800 0.0001% | $172.24 | $310,032 | +17.93% | |
| 2024-08-05 | Sale | GONZALEZ RICHARD A | EXECUTIVE CHAIRMAN OF BOARD | 66,500 0.0038% | $186.52 | $12.4M | +4.80% | |
| 2024-07-17 | Sale | GONZALEZ RICHARD A | EXECUTIVE CHAIRMAN OF BOARD | 282,845 0.016% | $175.00 | $49.5M | +9.60% | |
| 2024-03-20 | Sale | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 21,082 0.0012% | $176.30 | $3.72M | +3.60% | |
| 2024-03-18 | Sale | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | 58,949 0.0033% | $178.79 | $10.54M | +2.01% | |
| 2024-03-01 | Sale | RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | 75,680 0.0042% | $177.27 | $13.42M | +1.12% | |
| 2024-02-29 | Sale | Michael Robert A. | PRES & CHIEF OPERATING OFFICER | 68,879 0.0039% | $176.45 | $12.15M | +2.76% | |
| 2024-02-29 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 9,891 0.0006% | $177.39 | $1.75M | +2.76% |
| GONZALEZ RICHARD A | director | 388929 0.022% | $90.04M | 0 | 25 | |
| SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | 177292 0.01% | $41.04M | 0 | 20 | |
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 58247 0.0033% | $13.48M | 1 | 3 | +35.39% |
| Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | 53234 0.003% | $12.32M | 1 | 9 | +37.99% |
| Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | 11577 0.0007% | $2.68M | 0 | 4 | |
| Buckbee Kevin K | SVP, CONTROLLER | 11496 0.0007% | $2.66M | 0 | 3 | |
| RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | 6130 0.0003% | $1.42M | 0 | 24 | |
| Siatis Perry C | EVP, GC AND SECRETARY | 4619 0.0003% | $1.07M | 0 | 8 | |
| Schumacher Laura J | Vice Chairman | 213003 0.0121% | $49.31M | 1 | 14 | +27.77% |
| CHASE WILLIAM J | EVP, Finance & Administration | 169552 0.0096% | $39.25M | 1 | 7 | +28.07% |
| SEVERINO MICHAEL | Vice Chairman | 152103 0.0086% | $35.21M | 0 | 7 | |
| ALBAN CARLOS | Vice Chairman | 114899 0.0065% | $26.6M | 0 | 9 | |
| LEONARD JOHN M. | SVP, Chief Scientific Officer | 107320 0.0061% | $24.84M | 0 | 2 | |
| Michael Robert A. | PRES & CHIEF OPERATING OFFICER | 98645 0.0056% | $22.84M | 0 | 6 | |
| HURWICH THOMAS A. | VP, Controller | 67276 0.0038% | $15.57M | 0 | 7 | |
| Gosebruch Henry O | EVP, Chief Strategy Officer | 41623 0.0024% | $9.64M | 1 | 6 | +30.69% |
| TILTON GLENN F | director | 39735 0.0022% | $9.2M | 1 | 0 | <0.0001% |
| Strom Carrie C | 37921 0.0021% | $8.78M | 0 | 4 | ||
| AUSTIN ROXANNE S | director | 34483 0.002% | $7.98M | 4 | 3 | +31.05% |
| Sorg Elaine K. | SVP, US COMMERCIAL OPERATIONS | 35330 0.002% | $8.18M | 0 | 10 | |
| Durkin Brian L | VP, Controller | 19094 0.0011% | $4.42M | 3 | 3 | +36.78% |
| RAPP EDWARD J | director | 2875 0.0002% | $665,562.50 | 5 | 0 | +17.9% |
| WADDELL FREDERICK H | director | 2000 0.0001% | $463,000.00 | 1 | 0 | +22.2% |
$364,217,072 | 28 | 9.11% | $28.84B | |
$6,224,380 | 25 | 3.58% | $586.69B | |
$1,922,773,492 | 23 | 18.04% | $932.32B | |
$23,129,500 | 19 | 8.42% | $123.7B | |
AbbVie Inc. (ABBV) | $28,542,809 | 19 | 26.40% | $409.15B |
$2,523,290 | 18 | -0.87% | $156.81B | |
$17,274,470 | 17 | 3.96% | $303.26B | |
$356,328 | 15 | -42.83% | $70.98M | |
$3,170,734 | 10 | 3.98% | $198.8B | |
$3,933,798 | 8 | 12.50% | $192.28B | |
$252,679 | 2 | 0.47% | $1.92B | |
$8,176 | 1 | 13.73% | $48.58M |
| Increased Positions | 1,908 | +47.37% | 47M | +3.65% |
| Decreased Positions | 1,769 | -43.92% | 45M | -3.48% |
| New Positions | 274 | New | 4M | New |
| Sold Out Positions | 110 | Sold Out | 5M | Sold Out |
| Total Postitions | 4,167 | +3.45% | 1B | +0.17% |
| Vanguard Group Inc | $40.76M | 10.06% | 177.75M | +448,554 | +0.25% | 2025-09-30 |
| Blackrock, Inc. | $33.47M | 8.26% | 145.98M | -1M | -1% | 2025-09-30 |
| State Street Corp | $18.3M | 4.52% | 79.82M | -202,472 | -0.25% | 2025-09-30 |
| Jpmorgan Chase & Co | $12.96M | 3.2% | 56.53M | -679,591 | -1.19% | 2025-09-30 |
| Morgan Stanley | $9.55M | 2.36% | 41.65M | -45,217 | -0.11% | 2025-09-30 |
| Geode Capital Management, Llc | $9.27M | 2.29% | 40.44M | +1M | +3.22% | 2025-09-30 |
| Charles Schwab Investment Management Inc | $5.95M | 1.47% | 25.96M | -825,223 | -3.08% | 2025-09-30 |
| Capital Research Global Investors | $5.79M | 1.43% | 25.23M | -34,749 | -0.14% | 2025-09-30 |
| Bank Of America Corp /De/ | $5.77M | 1.42% | 25.15M | +45,260 | +0.18% | 2025-09-30 |
| Norges Bank | $5.3M | 1.31% | 23.1M | -2M | -7.94% | 2025-06-30 |